ARTICLE | Company News
Somatix gene/cell therapy news
October 7, 1996 7:00 AM UTC
In a cost reduction program, SOMA will delay a Phase II trial of its autologous GVAX cancer vaccine and reduce its staff to 82 employees from 122. SOMA said it will look to partner the program while c...